Taken together, these results indicate that although IGFBP2 expression is low in IDH-mutant gliomas of all three histological types, the increased expression is a powerful, negative prognostic marker that predicts a median overall survival worse than that of IDH-wildtype group. Here, IDH2 is linked to central nervous system cancer.